Annexuzlimab is a new specific monoclonal antibody designed to treat autoimmune diseases.

Its target is annexin-1, which is over-expressed in autoimmune disease, and is a key factor in the human immune system.

In extensive non-clinical testing, annexuzlimab has shown significant activity in rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.

Annexuzlimab, which has been humanised, has the potential to become a major new agent in the treatment of these complex conditions.

Latest News

March 2018

The application process is now open for the MedAnnex/University of Glasgow four-year PhD, "Annexin-A1 as a target for T cell mediated pathology in psoriatic arthritis”

February 2018

MedAnnex welcomes Prof Carl Goodyear to its┬áScientific Advisory Board. Carl is Professor of Translational Immunology at Glasgow University’s Institute of Infection, Immunity and Inflammation, and Director of the GLAZgo Discovery Centre.